The Globe and Mail: But access to the expensive treatment will depend on whether government drug plans opt to cover it, something they have so far declined to do for a similar medication that was greenlit by the federal regulator last year…
Health Canada approves second drug targeting underlying cause of Alzheimer’s disease
Subscribe
Login
0 Comments
Oldest